Moderna, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stéphane Bancel
- Full Time Employees
- 4,700
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Company News
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Moderna (MRNA) Rises Higher Than Market: Key Facts
Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher
What's Going On With Moderna Stock Monday?
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Why is Moderna down 10% on Friday?
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Dow, Nasdaq Diverge Again as AI Rotation Intensifies
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Meet the New Nasdaq-100 Stock That's Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
Moderna: Best S&P 500 Stock YTD Could Rally Into YE, But Valuation Is Uncertain
Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher